DEFA14A: Zimmer Biomet to Acquire Paragon 28 in Push for Foot and Ankle Market Dominance

Paragon 28 announces its acquisition by Zimmer Biomet, aiming to enhance its mission to improve surgical outcomes in the foot and ankle market.

Summary

• Paragon 28, Inc. is being acquired by Zimmer Biomet.
• The announcement was made on January 29, 2025.
• The deal has unanimous board approval from both companies.
• The acquisition is expected to close in the first half of 2025, pending regulatory approvals.
• Paragon 28 aims to become the first billion-dollar revenue pureplay foot and ankle company.
• The foot and ankle market is currently over $5 billion, with potential for significant growth.
• Paragon 28 will remain exclusively focused on foot and ankle products.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the acquisition announcement, highlighting the benefits for both companies and the potential for growth in the foot and ankle market. The management's comments are optimistic, and the deal has received unanimous board approval.

Positives

• The acquisition provides Paragon 28 with access to Zimmer Biomet's resources, a close to $8 billion organization.
• The deal is expected to accelerate Paragon 28's growth trajectory in the foot and ankle market.
• Both companies share a cultural alignment on improving patient outcomes.
• Paragon 28 will remain focused on foot and ankle, maintaining its specialization.
• The acquisition is the largest to date for Zimmer Biomet CEO Ivan Tornos.

Negatives

• The acquisition is subject to regulatory approvals, which could delay or prevent the deal from closing.
• There are risks associated with integrating the two businesses successfully.
• The announcement could negatively affect Paragon 28's stock price and operating results.

Risks

• The deal is contingent on obtaining necessary regulatory approvals.
• Competing offers for Paragon 28 could emerge.
• The transaction agreement could be terminated under certain circumstances.
• The anticipated benefits of the acquisition may not be realized.
• The integration of the two businesses may not be successful.
• The revenue milestone for contingent value rights may not be achieved.
• The acquisition could disrupt business and operational relationships.
• Management's attention could be diverted from ongoing business operations.
• Litigation or regulatory actions could arise in connection with the transaction.

Future Outlook

Paragon 28 anticipates closing the acquisition in the first half of 2025 and aims to continue its growth trajectory within Zimmer Biomet, focusing on the foot and ankle market.

Management Comments

• Albert DaCosta stated that the acquisition makes perfect sense in their quest to become the leader in the foot and ankle market.
• Albert DaCosta emphasized the cultural alignment with Zimmer Biomet and their shared passion for improving patient outcomes.
• Albert DaCosta highlighted the importance of not damaging the good stuff of Paragon 28 during the acquisition process.
• Albert DaCosta is looking forward to continuing to build the company with all employees as they conquer the foot and ankle market.

Industry Context

This acquisition reflects a trend of consolidation in the orthopedics industry, with larger players seeking to expand their presence in specialized segments like the foot and ankle market. Zimmer Biomet's move to acquire Paragon 28 is a strategic effort to strengthen its position in this growing market.

Comparison to Industry Standards

• Zimmer Biomet's acquisition of Paragon 28 is similar to Stryker's acquisition of Wright Medical in 2020, which also aimed to strengthen its position in the extremities market.
• The $5 billion foot and ankle market is smaller than the overall orthopedics market, but it is growing faster due to increasing demand for specialized treatments.
• Paragon 28's focus on innovation and technology in foot and ankle is comparable to companies like Arthrex and Acumed, which are also known for their specialized product offerings.

Stakeholder Impact

• Shareholders of Paragon 28 will receive consideration as part of the acquisition.
• Employees of Paragon 28 are expected to continue their work within Zimmer Biomet.
• Surgeons and patients are expected to benefit from the combined resources and innovation of the two companies.
• The acquisition could impact suppliers and other business partners of Paragon 28.

Next Steps

• Obtain regulatory approvals for the acquisition.
• Work towards closing the deal in the first half of 2025.
• Integrate Paragon 28 into Zimmer Biomet while preserving its focus on foot and ankle.
• Continue developing and launching new products in the foot and ankle market.

Key Dates

Keywords

acquisition, Zimmer Biomet, Paragon 28, foot and ankle market, merger, orthopedics, regulatory approvals